Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 2007

View Archived Issues

Synergistic effects of triple antiangiogenic therapy in preclinical models of neovascularization

PRX-302 shows promise for prostate cancer

Intravenous cannabinor shows no efficacy benefit in capsaicin-induced pain

New phase II study for PEP-005 Topical in actinic keratosis

FTC clears Hospira's acquisition of Mayne Pharma

Tentative approval for Barr's generic version of Kytril

Bionovo opens pharmacokinetics study of MF-101

Nalbuphine ER begins phase I safety study for pain

Bayer Schering signs agreement for novel neurodegenerative imaging compounds

MBP-8298 cleared to begin U.S. phase III study in secondary progressive MS

Recent Janssen and Aska patents report new therapeutic agents for urological disorders

Recent Merck, Ambrilia and AnorMED patents disclose novel therapeutics for HIV infection

Safety data from the STAR study presented

No benefit of adding bevacizumab to standard therapy in pancreatic cancer

New treatment options for cardiovascular disorders imparted in recent patents

Addition of bevacizumab to chemotherapy improves progression-free survival in MCRC patients

Final results from the ACTS-GC trial announced

AnGes inlicenses Naglazyme for Japan

Iomai awarded contract for adjuvant patch for use with pandemic influenza vaccine

Novel orally active oxytocin receptor antagonist profiled at GlaxoSmithKline

Novartis and Mochida to copromote Diovan in Japan

Johns Hopkins team reports favorable data on pancreatic cancer vaccine

FDA grants orphan drug status for droxidopa in neurogenic orthostatic hypotension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...